Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration.

Similarly to the CRT, PED height also showed a highly significant decrease in the responder group (median difference: − 21 μm, IQR: 36, range: [ −]307–2, p < 0.0001); while we observed no changes in PED height in the non-responder group (median difference: + 22 μm, IQR: 64, range: [ −]38–91, p = 0.1508) (Fig. 2 d–f).

also in 132,142 other papers